Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor
DALLAS, April 25, 2024 /PRNewswire/ -- Nanoscope Therapeutics, Inc. , a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced today the appointment of Allen C. Ho, MD, FACS, FASRS, as Chief Medical Advisor, where he will help define the strategy of developing the gene mutation-agnostic therapies.
- DALLAS, April 25, 2024 /PRNewswire/ -- Nanoscope Therapeutics, Inc. , a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced today the appointment of Allen C. Ho, MD, FACS, FASRS, as Chief Medical Advisor, where he will help define the strategy of developing the gene mutation-agnostic therapies.
- Dr. Ho is Attending Surgeon and Director of Retina Research at Wills Eye Hospital and Co-Director of the Wills Eye Hospital Retina Service.
- "We are excited to have Dr. Allen C. Ho join Nanoscope as Chief Medical Advisor," said Sulagna Bhattacharya, Nanoscope co-founder and CEO.
- "As a world-renowned retina specialist and leader in innovative treatments for retinal diseases, his insight will be invaluable to Nanoscope.